Sarepta Q1 2026 net income rises to $331.0 million; revenue dips 2%
Sarepta reported first quarter 2026 total revenues of $730.8 million, down $14.1 million or 2% from a year earlier, while GAAP net income was $331.0 million compared with a net loss of $447.5 million in the prior-year quarter. The filing attributes the profit swing largely to $365.0 million of collaboration revenue tied to Roche's declined option for certain program rights, and the company reiterated its full-year 2026 guidance.
Key points
- Total revenues were $730.8 million, versus $744.9 million a year earlier; net product revenues were $330.5 million, including $102.0 million from ELEVIDYS and $228.6 million from PMO products.
- GAAP diluted earnings per share were $2.88, compared with a loss of $4.60 per share in the first quarter of 2025.
- GAAP operating income was $358.4 million, compared with a loss of $300.4 million a year earlier; non-GAAP operating income was $397.7 million.
- Sarepta reiterated FY 2026 guidance of total net product revenues of $1.2 to $1.4 billion and combined non-GAAP R&D and SG&A expenses of $800.0 to $900.0 million.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.